JP2944008B2 - Parenteral lipid metabolism improver - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to a highly purified whey protein and / or a non- protein containing a hydrolyzate of the highly purified whey protein.
The present invention relates to an oral lipid metabolism improving agent, and a parenteral lipid metabolism improving agent containing high-purity whey protein and / or a hydrolyzate of the high-purity whey protein and indigestible dextrin. More specifically, the present invention relates to at least 85% (by weight) solids.
The same applies to whey proteins unless otherwise specified) and / or a hydrolyzate of the whey proteins containing at least 30% of the total protein contained in the final product. A high purity whey protein and / or a hydrolyzate of the high purity whey protein containing at least 85% of the total protein in the final product. % Cholesterol and high-density lipoprotein cholesterol (hereinafter, abbreviated as high-density lipoprotein), which contain indigestible dextrin at least 5% of the solid content of the final product. Parenteral that is effective in increasing and does not induce abnormal lipid metabolism
It relates to a lipid metabolism improving agent.

[0002]

2. Description of the Related Art In recent years, with an increase in animal fat intake,
In particular, an increase in blood cholesterol in middle-aged and elderly persons has been observed, which has become a major problem since it triggers various adult diseases (eg, arteriosclerosis). In addition, an increase in blood cholesterol in childhood predisposes to the development of adult diseases in the future, and is therefore regarded as a problem for childhood adult diseases.

[0003] From this point of view, studies of components that lower blood cholesterol, have been conventionally performed, for example, cholesterol synthesis inhibitors such as compactin, b
Synthetic physicians such as cholesterol excretion enhancers such as on-exchange resins
Drugs are used.

[0004] Among the food components that lower blood cholesterol, proteins and their hydrolysates have attracted attention in recent years. In particular, it has been reported that plant proteins such as soy protein have a remarkable blood cholesterol lowering effect as compared with animal proteins such as casein and fish meat protein. For example, Nagata et al. Report in animal experiments that soy protein lowers blood cholesterol and raises casein [British Journal of Nutritio
n), Vol. 44, p. 113, 1980].

On the other hand, milk contains more animal fat and cholesterol than other foods, and further contains casein which is a protein having a blood cholesterol-raising effect. There is no report that blood cholesterol is increased by ingestion, but it is reported that blood cholesterol is decreased. For example, Howard et al. Have found a blood cholesterol lowering effect in whole milk and skim milk [Atherosclerosis, 27th.
Vol. 383, 1977]. From these facts, the existence of blood cholesterol lowering factor in milk was estimated, and Yamauchi et al. Suggested non-protein low molecular components such as orotic acid, 3-hydroxy-3-methyl glutaric acid, lactose, and calcium. (Journal of the Society of Animal Husbandry, vol. 52, p. 71, 1981). Of these, orotic acid is effective in lowering blood cholesterol, but side effects such as induction of fatty liver are also known [Experiencia (Experiencia)].
tia), Vol. 30, p. 993, 1974). However, it has not been described in the literature that a high-purity whey protein of 85% or more and / or a hydrolyzate thereof is effective for improving lipid metabolism, and has not been known so far.

[0006] Conventionally, parenteral administration using whey protein
Pharmaceuticals ( eg, enteral nutrition supplements with whey protein)
Although present, the purity of whey proteins used in these oral drugs was less than 80% none, not permitted lipid metabolism improving effect in these products.

[0007] It is known that poorly absorbable substances, such as dietary fiber, have a blood cholesterol lowering effect (Satoshi Innan and Shupachi Kiriyama, "Dietary Fibers", p. 131, first publication, 1982). Year). Chen et al. Report that water-soluble dietary fiber has an effect of reducing hepatic and blood cholesterol in cholesterol-fed rats [Proceedings of the Society for Experimental Biology and Experiments].・ Medison (Proceedings of the Society for Experi-me)
ntal Biology and Medicine), 175, 215, 1984]. However, it has not been hitherto known that a synergistic blood cholesterol lowering effect is brought about by the combined use of high-purity whey protein of 85% or more and / or a hydrolyzate thereof and an indigestible dextrin.

[0008]

The present invention is to provide a blood cholesterol
If the level is high, the drug is administered or dietary restrictions are imposed. Synthetic physicians such as compactin and ion exchange resin
Drugs, to varying degrees, all have side effects, and dietary restriction is also undesirable. Therefore, it can be administered without limiting the diet, and the synthetic pharmaceuticals have side effects
Of pharmaceuticals that are safe ingredients
It would be very ideal if blood cholesterol could be reduced by parenteral administration .

[0009]

Means for Solving the Problems The present inventors have conducted intensive studies in order to realize this ideal, and suppose that there is a component effective in lowering blood cholesterol and increasing high density lipoprotein in milk components. As a result of screening the components based on the hypothesis, it was found that high-purity whey protein and its hydrolyzate were effective, and further, high-purity whey protein and / or its hydrolyzate It has been found that the combination of dextrin and indigestible dextrin synergistically lowers blood cholesterol and increases high-density lipoprotein, thus completing the present invention.

According to the invention, at least 85% of the solids
% Parenteral whey protein containing whey protein in a proportion of at least 30% of the total protein in the final product, and / or a hydrolyzate of said whey protein in a final product.
Lipid metabolism improving agents, and high purity whey protein containing whey protein at a ratio in the solid content of at least 85% and / or at least 20% of the total protein in the final product a high-purity whey protein hydrolyzate ratio in, and parenteral lipid metabolism improving agent is provided an indigestible dextrin each containing a proportion of solids of at least 5% of the final product, these parenteral lipid metabolism improving agent hypocholesterolemic and blood It is effective in increasing medium-density lipoprotein and does not induce abnormal lipid metabolism.

[0011] As described above, the conventionally using whey protein pharmaceuticals exist, either pure whey protein used in these pharmaceuticals are also less than 80%, surprisingly, low It was found that when whey protein having a purity was used, no effect of improving lipid metabolism was observed even if the content of whey protein was equal to the content in the present invention (see Test Example 1).

The method for producing the high-purity whey protein and its hydrolyzate used in the present invention is known per se, and can be produced, for example, from whey as follows.

Adjusting the whey to acidic (eg pH 4),
The obtained solution is passed through a column filled with a cation exchange resin, and the whey protein is adsorbed on the cation exchange resin. Thereafter, an alkaline solution (eg, pH 9) is passed through the column,
The whey protein is eluted, and the obtained eluate is concentrated by ultrafiltration while adding water by a conventional method, and the protein concentration in the solid component is 9%.
Purify to 5% and spray-dry if necessary to obtain high purity whey protein. The high-purity whey protein obtained as described above usually contains whey protein in a proportion of 85% or more in the solid content, and further contains about 5% of water, about 2% of ash, and a small amount of lactose and lipid. It contains. Further purification,
Nearly pure whey protein can also be obtained.

The hydrolyzate of high-purity whey protein can be produced by hydrolysis with an acid or an enzyme.

One example of the case of hydrolysis with an acid is that high purity whey protein is 0.1 to 20%, preferably 5 to 20%.
It is dissolved in water, purified water, etc. at a concentration of 、 15%, and an acid (inorganic acid or organic acid), for example, hydrochloric acid is added to the obtained solution in an amount of 0.5-5%.
At a concentration of 5 to 100 times the amount of the high-purity whey protein,
Hold at 70 to 120 ° C. for 0.5 to 100 hours to perform hydrolysis. Next, the reaction solution is neutralized, cooled, and if necessary, decolored, filtered, desalted, concentrated and dried by a conventional method. The hydrolysis conditions described above are not absolute and can be appropriately changed depending on the heating temperature, time, concentration and amount of the reagent used, and the like.

The enzyme used for the enzymatic hydrolysis is not particularly limited, and may be trypsin, chymotrypsin, subtilisin,
Commercially available proteases such as papain, pepsin and pancreatin, carboxypeptidase derived from yeast, aminopeptidase derived from lactic acid bacteria and the like can be used. These enzymes can be used in any combination. The amount of enzyme used is 0.1 to 5.0 relative to high purity whey protein.
%. The high-purity whey protein is dissolved in water, purified water or the like, and the enzyme is added to the resulting solution. The hydrolysis is adjusted to a pH around the optimal pH of the enzyme to be used within a range that does not denature the raw material whey protein,
Hold for 24 hours. Next, the reaction solution is directly or neutralized, and then the enzyme is inactivated by heating. After cooling, filtration, desalting, concentration and drying are carried out by a conventional method, if necessary, to obtain a hydrolyzate of high-purity whey protein ( (Hereinafter simply referred to as a hydrolyzate). In general, the conditions for preparing the hydrolyzate are not particularly strictly limited, and the production cost, for example,
The conditions are appropriately set in consideration of the temperature, time, type and amount of the enzyme, and the like.

The rate or degree of hydrolysis of the hydrolyzate does not significantly affect the effects of lowering blood cholesterol and increasing high density lipoprotein, but has special reasons such as loss of antigenicity of whey protein as a protein. In some cases, a hydrolyzate having a desired decomposition rate can be used. The decomposition rate can be calculated as a percentage of the amount of formol nitrogen with respect to the total amount of nitrogen by, for example, a formol titration method.

The hydrolyzate obtained as described above is
Extremely stable against heating, pH fluctuation, and oxidation
It consists of a mixture of peptides with different molecular weights.

In the present invention, a high-purity whey protein and / or a hydrolyzate thereof may be used irrespective of whether the parenteral lipid metabolism improving agent contains protein or dextrin in the material. , Irrespective of whether the protein or dextrin is inherently contained in the parenteral lipid metabolism-improving material, at least 30% (preferably 70 to 100%) of the total protein in the final product. ,
The high-purity whey protein and / or its hydrolyzate comprises at least 20% (preferably 70-100%) of the total protein in the final product and at least 5% of the solids content of the final product. It is characterized by containing indigestible dextrin, and there is no limitation on means for realizing their content. In other words, replaced with original parenteral lipid metabolism improving agent protein contained in the raw material part or all of high purity whey protein and / or a hydrolyzate thereof, or parenterally lipid allowance
High purity whey protein and / or a hydrolyzate thereof is added to the material for improving the quality of whey, and the above-mentioned content of high purity whey protein and / or its hydrolyzate in the final product (20% or more of the total protein) , Or 30% or more),
Alternatively, a part or all of the dextrin originally contained in the parenteral lipid metabolism improving agent material is replaced with an indigestible dextrin, or an indigestible dextrin is added to the parenteral lipid metabolism improving agent material, and finally, The above-mentioned content of indigestible dextrin in the product (5% or more in solid content) can be achieved. At this time, the upper limit of the replacement amount or the addition amount may be appropriately determined within a range that does not impair the physical properties, flavor and the like of the final product.

The indigestible dextrin used in the present invention may be a commercially available product, for example, Pine Fiber (trademark, manufactured by Matsutani Chemical Industry Co., Ltd.) is commercially available. Indigestible dextrins can be obtained from commercially available corn starch, potato starch, sweet potato starch, wheat starch, rice starch, tapioca starch and the like, for example, from JP-A-2-100695 and JP-A-Hei2.
It can also be produced by a method described in JP-A-145169, JP-A-2-154664, or the like. One example is described below for reference.

An aqueous solution of a mineral acid, preferably hydrochloric acid, is added to the raw starch, dried at 100 to 120 ° C. to a water content of about 5%, and then roasted at 150 to 220 ° C. for 1 to 5 hours to obtain the roasted dextrin. obtain. This roasted dextrin is 30 ~
Dissolve in water at a concentration of 50% and adjust the pH of the solution to 5.5-6.
5, α-amylase in a ratio of 0.05 to 0.2% of roasted dextrin was added and allowed to act for 30 to 120 minutes, heated to 120 ° C. to inactivate the enzyme, cooled, and cooled.
H adjustment, transglucosidase alone or a combination of transglucosidase and β-amylase,
Is added at a ratio of 0.05 to 0.2% of the roasted dextrin and allowed to act for 24 to 48 hours, and then heated to inactivate the enzyme, thereby obtaining an indigestible dextrin.

The indigestible dextrin produced as described above contains at least 5% of the solid content of the final product, preferably 10 to 40, as apparent from Test Example 3 described below.
%, And mixed.

In preparing the parenteral lipid metabolism-improving agent of the present invention, a special method is not required, and it may be appropriately replaced and mixed in an appropriate step of a usual production method of each drug. For example, for a protein material such as casein, soy protein, egg white, fish meat protein, livestock meat protein, or a material containing a protein such as skim milk, whole milk, soy milk, etc., the material contains high-purity whey protein and / or Add desired amount of hydrolyzate (30% or more or 20% or more)
The protein-free material can be produced by adding a desired amount of high-purity whey protein and / or a hydrolyzate thereof, and then producing the parenteral lipid metabolism improving agent according to the respective method. In the production of a product using indigestible dextrin in combination, high-purity whey protein and / or its hydrolyzate is added at a ratio of at least 20% as described above, and at least 5% of the solid content of the final product is added. in addition of indigestible dextrin, parenteral fat subsequent respective
It can be produced according to a method for producing a quality metabolism improving agent . Next, the present invention will be described in detail with reference to test examples.

[Test Example 1] This test was conducted to examine the effect of high-purity whey protein and its hydrolyzate on improving lipid metabolism.

1) Preparation of Feed Five kinds of feeds having the compositions shown in Table 1 were prepared by changing only the type of protein. Cholesterol and cholic acid are added to these feeds, and the added amount is sufficient to increase blood cholesterol if the compounded protein does not have an effect of improving lipid metabolism. In addition, each protein is
The amount of nitrogen was measured by a conventional method, and each feed was blended so that the amount of nitrogen (protein content) was the same, and the total amount was adjusted with sucrose.

[0026]

[Table 1] 2) Test method Eight SD rats were divided into five groups of eight rats, and each group was allowed to freely take feed and water containing different proteins. The protein in the feed given to each group is as follows.

Group 1: casein (manufactured by Oriental Yeast Co., Ltd., containing no vitamin) Group 2: high-purity whey protein (prepared by the same method as in Reference Example 1; purity: 85%) Group 3: hydrolyzate (Prepared by the same method as in Reference Example 2. Hydrolyzate of high-purity whey protein having a purity of 85%) Group 4: Low-purity whey protein obtained by a conventional method (by the same method as in Reference Example 3) Purity 75%, except that the content of whey protein is the same as the content of whey protein in group 3). Group 5: Commercial soybean protein Fujipro R (trademark, manufactured by Fuji Oil Co.) Blood was collected from each rat three weeks after the start of breeding, and serum cholesterol level, serum high-density lipoprotein level, and serum triglyceride level were measured. Then, the average value of each group was calculated, and the serum cholesterol lowering, the high-density lipoprotein increase, and the change of serum triglyceride by the feed were tested.

The serum cholesterol value was determined by an enzyme method using a cholesterol E test (manufactured by Wako Pure Chemical Industries), and the serum high density lipoprotein value was determined by using an HDL cholesterol E test (manufactured by Wako Pure Chemical Industries). The serum neutral fat level was measured by the enzyme method using the triglyceride E test (manufactured by Wako Pure Chemical Industries, Ltd.) by the precipitation / enzyme method, and the average value of each group was calculated.

3) Test results The results of this test are as shown in Table 2, and the numerical values are shown as the average value of each test group.

[0030]

[Table 2] The mean serum cholesterol level and serum high-density lipoprotein level in the second group (high-purity whey protein-administered group) were those of the fifth group (soy-protein-administered group that was said to lower serum cholesterol). About 54% (reduction)
And about 2.4 fold (increase), about 39% (decrease) and about 1.8 fold (increase) of those of the first group (casein administration group), and the fourth group (low-purity whey protein). About 76% (decrease) and about 1.2 times (increase) of those of the
The serum cholesterol level of the second group to which the high-purity whey protein of the present invention was administered was clearly reduced, and the high-density lipoprotein was significantly increased.

On the other hand, the serum cholesterol level and the serum high-density lipoprotein level of the third group (hydrolyzate-administered group) were as follows:
About 54% (reduced) and about 2.3 times (increased) of those of the fifth group (soy protein-administered group), and about 40% (decreased) and about 1% of those of the first group (casein-administered group) 0.7 fold (increase), about 77% (decrease) and about 1.1 fold (increase) of those of the fourth group (low-purity whey protein administration group), and the second group (high-purity whey protein). Although the effect was inferior to that of the protein-administered group, the serum cholesterol level was clearly decreased and the serum high-density lipoprotein was clearly increased as compared with the control group.

The average value of the ratio of high-density lipoprotein to cholesterol in each group 25 days after the start of breeding was as follows:
Group 0.084, second group 0.372, third group 0.355,
The fourth group was 0.246, the fifth group was 0.084, and the high-purity whey protein administration group (second group) and the hydrolyzate administration group (third group)
Group) was significantly improved over the other groups.

An increase in serum triglyceride is known as a risk factor for the development of arteriosclerosis together with an increase in serum cholesterol, but the values in groups 2 and 3 were normal, whereas In the fourth group to which the pure whey protein was administered, the serum neutral fat content was significantly increased.

From the above results, it was proved that high-purity whey protein and its hydrolyzate were effective for improving lipid metabolism.

The same test was carried out by changing the content of each protein in the feed and the degradation rate of the hydrolyzate in various ways.
Almost the same result was obtained.

[Test Example 2] In this test, lipids were obtained in the same manner as in Test Example 1 except that the diet in which the protein in the feed was replaced with high-purity whey protein at various ratios was administered to five groups of SD rats. It was performed to examine the metabolic improvement effect.

1) Preparation of feed The following five types of compositions shown in Table 1 of Test Example 1 were used in which casein was replaced with high-purity whey protein at different ratios based on a feed containing casein as a protein source. Were prepared and administered to each group.

Group 1: feed containing casein as a protein source, Group 2: feed containing 20% of casein replaced by high-purity whey protein, Group 3: replacement of 30% of casein by high-purity whey protein Group 4: a feed in which 70% of casein was replaced by high-purity whey protein, Group 5: a feed in which 100% of casein was replaced by high-purity whey protein, 2) Test method Same as in Test Example 1. The effect of each feed on improving lipid metabolism was tested by the method described in the above.

3) Test results The results of this test were as shown in Table 3.

[0040]

[Table 3] As is clear from Table 3, the third group (30% substitution), the fourth group
In group (70% replacement) and group 5 (100% replacement), serum cholesterol was decreased, serum high-density lipoprotein was increased, and serum triglyceride was lower than in control (casein-administered) group 1. No change was observed. Therefore,
It has been found that substitution of at least 30% of the protein in the feed with high-purity whey protein is effective for improving lipid metabolism. The higher the substitution ratio of the high-purity whey protein, the higher the effect of improving lipid metabolism.
It is desirable to be in the range of 0%. The same test as described above was performed for the hydrolyzate, and almost the same results were obtained.

[Test Example 3] This test was conducted to examine the effect of improving lipid metabolism on animals to which a diet in which the protein and dietary fiber in the diet were changed at various ratios was administered.

1) Preparation of Feed 10 kinds of feeds were prepared by changing the components as shown in Table 1 in Test Example 1 as follows, and administered to SD rats of each group in the same manner as in Test Example 1. did.

Group 1: The total amount of protein is defined as casein,
Feed from which cellulose has been removed (however, the total amount is adjusted with sucrose; the same applies hereinafter) Group 2: Feed containing 5% of cellulose (manufactured by Oriental Yeast Co., Ltd.) and Casein the total amount of protein , A feed containing 2.5% of commercially available indigestible dextrin (Matsuya Chemical Industry Co., Ltd.) after removing cellulose. Group 4: The whole amount of protein is made into casein, and cellulose is removed to remove commercially available indigestible dextrin ( Feed containing 5% of Matsuya Chemical Industry Co., Ltd. Group 5: Feed containing 10% of commercially available indigestible dextrin (Matsuya Chemical Industry Co., Ltd.) after removing all cellulose as casein and removing cellulose. : Feed from which 20% of casein was replaced by high-purity whey protein and cellulose was removed. Group 7: 20% of casein was replaced by high-purity whey protein, and cellulose (O Group 8: 20% of casein is replaced with high-purity whey protein, cellulose is removed, and commercially available indigestible dextrin (manufactured by Matsutani Chemical Industry Co., Ltd.) is used. Feed containing 5% added Group 9: Feed containing 20% of casein replaced with high-purity whey protein, cellulose removed, and 5% of commercially available indigestible dextrin (Matsuya Chemical Industries) added. : Feed in which 20% of casein was replaced by high-purity whey protein, cellulose was removed, and 10% of commercially available indigestible dextrin (manufactured by Matsutani Chemical Industry Co., Ltd.) was added 2) Test method The same method as in Test Example 1 The effect of each feed on improving lipid metabolism was tested.

3) Test results The results of this test were as shown in Table 4. As is clear from Table 4, in Groups 4 and 5 (administration of a feed containing 5% or more of indigestible dextrin), the first group (control, administration of a diet without dietary fiber) and the second group ( As compared with administration of a cellulose-added feed), serum cholesterol was reduced and high-density lipoprotein was increased, and as is conventionally known, indigestible dextrin itself had an effect of improving lipid metabolism. However, the effect when 5% or more of indigestible dextrin was added was confirmed in Test Example 1.
And the effect of the high-purity whey protein and its hydrolyzate observed in Test Example 2 was not as remarkable (second test example 1).
Group and third group, and third group, fourth group and fifth group in Test Example 2).

The second group of Test Example 2 and the sixth group of Test Example 3
As is clear from the results of the group and the group 7, 20% of the protein
Was replaced only by high-purity whey protein (the second group of Test Example 2) and when 20% of the protein was replaced by high-purity whey protein and no indigestible dextrin was added (Test Example 3). Groups 6 and 7) did not show any significant lipid metabolism-improving effect. However, feed containing 20% of protein replaced with high-purity whey protein and further added with 5% or more of indigestible dextrin was used. In the ninth and tenth groups that were administered, a remarkable effect of improving lipid metabolism was observed, and a synergistic effect of the combined use of high-purity whey protein and indigestible dextrin was clearly observed.

Thus, by replacing at least 20% of the protein in the final product with high-purity whey protein and adding indigestible dextrin in a proportion of at least 5% of the final product solids, the synergistic lipid The effect of improving metabolism is exhibited. In addition, the higher the proportion of the indigestible dextrin added, the higher the effect of improving lipid metabolism. However, the addition of 50% or more does not provide a favorable texture, so that the proportion of the indigestible dextrin is 10 to 40%. Range is desirable.

It should be noted that substantially the same results as described above were obtained for the hydrolyzate of high-purity whey protein. When the addition ratio of indigestible dextrin was less than 5%, no remarkable effect of improving lipid metabolism was observed.

[0048]

[Table 4] [Test Example 4] In this test, a feed in which indigestible dextrin was added at a ratio of 5% of the solid content of the feed and the protein (casein) in the feed was replaced with a high-purity whey protein at various ratios was administered. The test was performed to examine the effect of improving lipid metabolism on the five groups of SD rats. 1) Preparation of Feed Five kinds of feeds having the compositions shown in Table 5 in which the proteins were changed as described below were prepared and administered to SD rats in each group in the same manner as in Test Example 1.

Group 1: a feed in which the total amount of protein was casein, Group 2: a feed in which 10% of casein was made of high-purity whey protein, Group 3: a feed in which 20% of casein was made of high-purity whey protein Feed, Group 4: feed containing 50% of casein with high-purity whey protein, Group 5: feed containing 100% of casein with high-purity whey protein,

[Table 5] 2) Test method The lipid metabolism improving effect of each feed was tested by the same method as in Test Example 1.

3) Test results The results of this test were as shown in Table 6. As is clear from Table 6, when the indigestible dextrin was added to the feed at a ratio of 5% of the solid content of the feed, casein was reduced by 20%.
Serum cholesterol was significantly reduced in the third, fourth, and fifth groups to which the feed replaced with the high-purity whey protein at the above ratio was lower than the first group (casein administration) as a control, and Increased serum high density lipoprotein. Therefore, based on these results and the results of Test Example 3, in a feed in which at least 20% of the protein was replaced with high-purity whey protein, the addition of indigestible dextrin of at least 5% of the solid content of the feed had an effect on improving lipid metabolism. It has been found that they act synergistically. In addition, about the hydrolyzate of high purity whey protein, almost the same result was obtained.

[0051]

[Table 6] In the present invention, the separation of high-purity whey protein from whey, preparation of enzymatic hydrolyzate of high-purity whey protein, and a method for separating low-purity whey protein from whey are described below for reference only. .

Reference Example 1 30 g of CM swollen with warm water
-16 kg of whey adjusted to pH 4 with hydrochloric acid was added to Sephadex C-50 (manufactured by Pharmacia), stirred for 16 hours, then the ion exchange resin was separated by filtration, the ion exchange resin was washed with water, and the whey was removed. And packed in a column. Subsequently, a 5% aqueous sodium chloride solution was passed through to elute whey proteins adsorbed on the ion exchange resin, and the eluate was separated by an ultrafiltration membrane having a molecular weight cut-off of 20,000 (manufactured by DDS, GR61p).
Average pressure 3kg / c using module equipped with p)
Ultrafiltration was performed using m ² , water was added, diafiltration was performed to remove sodium chloride, and lyophilization was performed to obtain about 45 g of a high-purity whey protein powder. The whey protein content of this powder was 91.2%.

Reference Example 2 To 1 kg of high-purity whey protein powder produced by the same method as in Reference Example 1, 19 kg of water was added and dissolved, heated to 50 ° C., and 10 g of pancreatin (Amano Pharmaceutical Co., Ltd.) The mixture was maintained at the same temperature for 6 hours with stirring, then heated at 85 ° C. for 10 minutes to inactivate the enzyme, cooled to 20 ° C., filtered through a high flow super cell, and the filtrate was 35% And freeze-dried to obtain about 0.95 kg of a hydrolyzate powder.

Reference Example 3 16 kg of whey was subjected to ultrafiltration in the same manner as in Reference Example 1, water was added, diafiltration was carried out to remove low molecular fractions, and lyophilization was carried out. About 57 g of powder was obtained. The whey protein content of this powder was 75.1%.

Next, the present invention will be described in more detail by way of examples, but the present invention is not limited to the following examples.

[0056]

【Example】

[0057]

Example 1 1.3 kg of high-purity whey protein (protein content 92%) produced by the same method as in Reference Example 1 and commercially available casein powder (manufactured by New Zealand Daily Board; protein content 86)
%) And 1.4 kg of commercially available soybean protein (manufactured by Fuji Oil Co., protein content 86%) were dissolved in 60 l of warm water. 12.5 kg of commercially available dextrin (manufactured by Matsutani Chemical Industry Co., Ltd.) and commercially available vegetable oil (manufactured by NOF Corporation) were added to this solution.
3 kg, vitamins and minerals were added, mixed and homogenized, the total amount was adjusted to 100 l, and heat sterilized at 150 ° C. for 2 seconds to obtain about 100 kg of a liquid parenteral lipid metabolism improving agent . The protein content of this liquid parenteral lipid metabolism improver is 4
% Of which about 30% consisted of high-purity whey protein.

[0059]

[0060]

[0061]

[0062]

[0063]

[0064]

Example 2 1.3 kg of a high-purity whey protein hydrolyzate (protein content 93%) produced in the same manner as in Reference Example 2 and a commercially available casein powder (New Zealand Daily Board; protein content 85%) ) 1.8 kg and 1.4 kg of commercially available soybean protein (manufactured by Fuji Oil Co., protein content 88%) in 60 l of hot water
Was dissolved. To this solution, 4.5 kg of a commercially available dextrin (manufactured by Matsutani Chemical Industry Co., Ltd.), 8.0 kg of a commercially available indigestible dextrin (manufactured by Matsutani Chemical Industry Co., Ltd.), 3 kg of a commercially available vegetable oil (manufactured by NOF Corporation), vitamins and minerals ,
Mix, homogenize, adjust total volume to 100 l,
And heat sterilization for 2 seconds with a liquid parenteral lipid metabolism improver about 1
00 kg was obtained.

The protein content of this liquid enteral nutritional supplement is 4%, 30% of which consists of hydrolyzate of high-purity whey protein, and about 40% of 20% solids is indigestible dextrin. Was.

[0067]

[0068]

[0069]

[0070]

[0071]

[0072]

[0073]

[0074]

The effects of the present invention are as follows.

(1) Blood cholesterol can be reduced by taking the parenteral lipid metabolism improving agent of the present invention.

(2) The high-density lipoprotein in blood can be increased by taking the parenteral lipid metabolism improving agent of the present invention.

(3) By taking the parenteral lipid metabolism improving agent of the present invention, adult diseases caused by an increase in blood cholesterol level can be prevented.

(4) By taking the parenteral lipid metabolism improving agent of the present invention, undesirable lipid metabolism abnormalities are not induced.

[0079]

Continued on the front page (72) Inventor Yasuhiro Takeda 19-30 Nishikawashima-cho, Asahi-ku, Yokohama-shi, Kanagawa Prefecture Angel Heights 202 (72) Inventor Norio Murata 2078-31, Tamagawa-mura, Okawa-shi, Tamagawa-mura, Saitama-gun, Saitama Prefecture (72) Inventor Michio Ikeda 201, Stork Heights Kishi, 2-16 Higashi-cho, Isogo-ku, Yokohama-shi, Kanagawa Prefecture (56) References JP-A-2-104246 (JP, A) (58) Fields investigated (Int. Cl. ⁶ , DB name) A61K 38/17 A23L 1/305 JICST file (JOIS) MEDLINE (STN)

Claims (2)

(57) [Claims] 1. A high-purity whey protein and / or a hydrolyzate of the high-purity whey protein containing at least 85% (by weight) of whey protein in the solid content, wherein at least A parenteral lipid metabolism improving agent, which is contained at a ratio of 30% (by weight) . 2. A high-purity whey protein and / or a hydrolyzate of said high-purity whey protein containing at least 85% (by weight) of whey protein in the solid content, Parenteral , characterized in that it contains 20% (by weight) and indigestible dextrin in at least 5% (by weight) of the solid content of the final product.
Lipid metabolism improver.